Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study -北京协和医院 - 协和医院,北京协和医院,協和醫院,北京协和医院首页,北京协和医院电话,协和,協和,医院,醫院,北京協和醫院,北京协和医院妇科,北京协和医院地址,挂号

Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study

时间：2024.04.25 发布来源：本站原创

Hu X1, Cui X1, Wang Z, et al. Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study. BMC Cancer. 2023; 23(1):331.

上一条：Development and va...

下一条：Novel Structure-Dr...